Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

The Mid Valley community is mourning the loss of 20-year-old Eddie Kauffman, a beloved athlete, friend, and inspiration whose ...

A native of Southern California and a Crespi Carmelite High School graduate, Kyle Owens received his devastating leukemia ...

Panelists discuss how the greatest unmet needs include addressing poor outcomes in specific subsets like TP53-mutant disease, ...

Brayden Cabral has been in remission for some time but he serves as inspirations for others who have gone or will go through a similar experience.

A heartfelt cook dedicated to my niece Chelsey, who lost her battle with Acute Myeloid Leukemia in 2012. For the #CookingAgainstCancer collaboration, I’m grilling juicy porterhouse steaks and brown ...

Leukemia cells evade immune attack via SLAMF6, and by blocking this protein with a new antibody, researchers restored T cell function in AML.

This comprehensive nationwide study of acute leukaemia incidence, mortality and survival outcomes across China establishes ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

Spontaneous regression is most commonly reported in neuroblastoma and leukemia. Case series link infection, transfusion, and ...

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it has received clearance to begin pediatric enrolment in its phase 1 trial of a leukemia treatment.

Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to ...